- Home
- CTSO vs MAIA Comparison
CTSO vs MAIA Comparison
Compare CTSO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- MAIA
- Stock Information
- Founded
- CTSO 1997
- MAIA 2018
- Country
- CTSO United States
- MAIA United States
- Employees
- CTSO N/A
- MAIA N/A
- Industry
- CTSO Medical/Dental Instruments
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- MAIA Health Care
- Exchange
- CTSO Nasdaq
- MAIA Nasdaq
- Market Cap
- CTSO 48.2M
- MAIA 52.7M
- IPO Year
- CTSO N/A
- MAIA 2022
- Fundamental
- Price
- CTSO $0.86
- MAIA $1.98
- Analyst Decision
- CTSO Strong Buy
- MAIA
- Analyst Count
- CTSO 3
- MAIA 0
- Target Price
- CTSO $4.67
- MAIA N/A
- AVG Volume (30 Days)
- CTSO 135.6K
- MAIA 175.0K
- Earning Date
- CTSO 11-07-2024
- MAIA 11-12-2024
- Dividend Yield
- CTSO N/A
- MAIA N/A
- EPS Growth
- CTSO N/A
- MAIA N/A
- EPS
- CTSO N/A
- MAIA N/A
- Revenue
- CTSO $37,739,531.00
- MAIA N/A
- Revenue This Year
- CTSO $8.08
- MAIA N/A
- Revenue Next Year
- CTSO $12.80
- MAIA N/A
- P/E Ratio
- CTSO N/A
- MAIA N/A
- Revenue Growth
- CTSO 1.80
- MAIA N/A
- 52 Week Low
- CTSO $0.70
- MAIA $0.95
- 52 Week High
- CTSO $1.97
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- CTSO 42.77
- MAIA 45.13
- Support Level
- CTSO $0.80
- MAIA $1.93
- Resistance Level
- CTSO $1.09
- MAIA $2.63
- Average True Range (ATR)
- CTSO 0.08
- MAIA 0.20
- MACD
- CTSO -0.00
- MAIA 0.03
- Stochastic Oscillator
- CTSO 13.19
- MAIA 37.37
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.